AI assistant
GILEAD SCIENCES, INC. — Director's Dealing 2016
Dec 5, 2016
29828_dirs_2016-12-05_8af63179-d177-4fbb-8d03-2cc756ead1e5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2016-12-01
Reporting Person: MARTIN JOHN C (Director, Executive Chairman)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-12-01 | Common Stock | M | 100000 | $16.395 | Acquired | 3231096 | Direct |
| 2016-12-01 | Common Stock | S | 100000 | $73.3287 | Disposed | 3131096 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-12-01 | Non-qualified Stock Option (Right to Buy) | $16.395 | M | 100000 | Disposed | 2017-01-22 | Common Stock (100000) | Direct |
Footnotes
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
F3: Sale prices reported for the transactions reported here range from $72.84 to $73.83. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.